High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients | Zendy

D. Rey | Zendy; Bruno Hoën | Zendy; P. Chavanet | Zendy; MariePaule Schmitt | Zendy; Guillaume Hoizey | Zendy; P. Meyer | Zendy; Gilles Peytavin | Zendy; Bruno Spire | Zendy; Clotilde Allavena | Zendy; Myriam Diemer | Zendy; T. May | Zendy; J.L. Schmit | Zendy; Michel Duong | Zendy; Vincent Cálvez | Zendy; Jean-Marie Lang | Zendy

Open Access

High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients

Author(s) -

D. Rey,

Bruno Hoën,

P. Chavanet,

MariePaule Schmitt,

Guillaume Hoizey,

P. Meyer,

Gilles Peytavin,

Bruno Spire,

Clotilde Allavena,

Myriam Diemer,

T. May,

J.L. Schmit,

Michel Duong,

Vincent Cálvez,

Jean-Marie Lang

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn471

Subject(s) - nevirapine , lamivudine , zidovudine , medicine , viral load , resistance mutation , reverse transcriptase inhibitor , gastroenterology , virology , abacavir , reverse transcriptase , human immunodeficiency virus (hiv) , biology , viral disease , virus , antiretroviral therapy , hepatitis b virus , rna , biochemistry , gene

The combination of one non-nucleoside reverse transcriptase inhibitor (NNRTI) with two nucleoside reverse transcriptase inhibitors is a validated first-line antiretroviral (ARV) therapy. The once-daily combination of lamivudine, tenofovirDF and nevirapine has not been evaluated in a clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research